Engineered CAR Macrophages & Monocytes – Hijacking the Solid Tumor Microenvironment

Time: 12:45 pm
day: Day One


  • Outline challenges that the solid tumor microenvironment imposes onto adoptive cellular therapies
  • Discuss Carisma’s first-in-class myeloid cell therapies: CAR macrophages and CAR monocytes
  • Discuss CT-0508 (Anti-HER2 CAR-M): Pre-clinical data, impact on the solid TME, and interaction with the endogenous immune system